Corvus Pharmaceuticals (CRVS) Other Accumulated Expenses (2015 - 2026)

Corvus Pharmaceuticals' Other Accumulated Expenses history runs 12 years deep, the most recent figure standing at $206000.0 for Q1 2026.

• In Q1 2026, Other Accumulated Expenses fell 30.41% year-over-year to $206000.0; the TTM figure through Mar 2026 stood at $206000.0 (down 30.41% YoY), while the FY2025 annual figure was $238000.0, down 17.65% from the prior year.
• Other Accumulated Expenses for Q1 2026 stood at $206000.0, down from $238000.0 in the prior quarter.
• The five-year high for Other Accumulated Expenses was $566000.0 in Q3 2025, with the low at $131000.0 in Q2 2022.
• The 5-year median for Other Accumulated Expenses is $238000.0 (2025), against an average of $261411.8.
• The sharpest annual moves came in 2022 and 2023: Other Accumulated Expenses slumped 66.78% in 2022, then soared 85.78% in 2023.
• Corvus Pharmaceuticals' Other Accumulated Expenses stood at $158000.0 in 2022, then jumped by 55.06% to $245000.0 in 2023, then advanced by 17.96% to $289000.0 in 2024, then retreated by 17.65% to $238000.0 in 2025, then dropped by 13.45% to $206000.0 in 2026.
• Business Quant data shows CRVS's Other Accumulated Expenses at $206000.0 in Q1 2026, $238000.0 in Q4 2025, and $566000.0 in Q3 2025.